Celltrion is expanding its market presence in Peru, a major Latin American country, by winning a series of successful public tenders.
First of all, Truxima (rituximab) 500 mg won a tender held by the National Health Ministry of Peru (Centro Nacional de Abastecimiento de Recursos Estratégicos en Salud, CENARES), which is the largest public sector market in Peru. In addition, Truxima 100 mg won an EsSalud (Workers’ Insurance System in Peru) tender, giving Celltrion a share of more than 50 percent of the Peruvian Rituximab market with these two wins.
With these wins, Celltrion will supply Truxima 59 mg to the Ministry of Health on two occasions and Truxima 100 mg to EsSalud for one year starting February.
The tender held by EsSalud also included the biosimilar Herzuma (trastuzumab), an anti-cancer drug used to treat breast cancer and stomach cancer. The tender covers 53 percent of the trastuzumab market in Peru and is the largest ever. Herzuma will be supplied for one year beginning from this month.
Celltrion continued to win tenders not only for anti-cancer products but for products for autoimmune diseases. Celltrion also announced that Yuflyma (adalimumab) won the first tender for adalimumab in Peru, proving the product’s strong competitiveness. The tender was organized by EsSalud and the volume is said to account for approximately 20 percent of the Peruvian adalimumab market.
Celltrion’s Peruvian corporation employed a market-centric strategy and the strategy paid off in the public organization market in Peru. Celltrion’s Peruvian operations have been successful in winning local tenders over the years, according to Celltrion, which implemented an optimized strategy based on a comprehensive analysis of factors such as prices, volume, and the supply trends of products that won the tenders.
Celltrion expects to continue its success in the Peruvian market with the launch of Remsima SC and Vegzelma (bevacizumab). Remsima SC is the world’s first SC formulation of biosimilar infliximab. Vegzelma is a vascular endothelial growth factor (VEGF) inhibitor biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer including colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer and epithelial ovarian, fallopian tube, or primary peritoneal cancer.